Brief: Poxel Announces Positive Histology Results In PXL065 Trial

Poxel SA

21/09/2022 06:38

Sept 21 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL ANNOUNCES POSITIVE HISTOLOGY RESULTS FROM PHASE 2
NASH
TRIAL (DESTINY-1) FOR PXL065, A NOVEL, PROPRIETARY
DEUTERIUM-STABILIZED R-STEREOISOMER OF PIOGLITAZONE
    * ADDITIONAL BENEFITS ON GLUCOSE CONTROL (HBA1C) AND
MULTIPLE
INDICES OF INSULIN SENSITIVITY
    * PXL065 PHASE 2 TRIAL FOR TREATMENT OF NASH MET ITS PRIMARY
EFFICACY ENDPOINT FOR LIVER FAT CONTENT REDUCTION AT 36-WEEKS
FOR ALL DOSES
    * VALIDATION OF PXL065 HYPOTHESIS - COMBINING EFFICACY ON
LIVER
AND METABOLIC ENDPOINTS WITH REDUCED POTENTIAL FOR PPARΓ SIDE
EFFECTS (WEIGHT GAIN AND EDEMA)

Source text for Eikon:  ID:nBw5LvZKwa 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))